ASO - LULU FRO and PMCB among pre market gainers
Soligenix (NASDAQ:SNGX) +26% FDA Grants soligenix orphan drug designation for the treatment of T-cell lymphoma Eloxx Pharmaceuticals (NASDAQ:ELOX) +22% announces fast track designation for ELX-02 for the treatment of cystic fibrosis patients with nonsense mutations Cardiff Oncology (NASDAQ:CRDF) +16% after reporting new data from colorectal cancer trial ProQR Therapeutics (NASDAQ:PRQR) +14%. Lululemon Athletica (NASDAQ:LULU) +13%. Gold Royalty (NYSE:GROY) +11%. MIND Technology (NASDAQ:MIND) +11% on Q2 earnings. The Lovesac (NASDAQ:LOVE) +10% on Q2 earnings. Longeveron (NASDAQ:LGVN) +8% announces final results of Phase 1 clinical study of Lomecel-B Injection in hypoplastic left heart syndrome patients PharmaCyte Biotech (NASDAQ:PMCB) +7%. Blade Air Mobility (NASDAQ:BLDE) +7%. Innate Pharma (NASDAQ:IPHA) +7%. Rocket Lab (NASDAQ:RKLB) +7% reports 1H results. Enveric Biosciences (NASDAQ:ENVB) +6% announces MagicMed Industries' presentations at the following investor conferences in September Hepion Pharmaceuticals (NASDAQ:HEPA) +6%. SPI Energy (NASDAQ:SPI) +6% celebrates roll-out of first prototype of EdisonFuture electric pickup truck - EF1-T Hyzon Motors (NASDAQ:HYZN) +6%. Support.com (NASDAQ:SPRT) +5%. Frontline (NYSE:FRO) +5%. Academy Sports
For further details see:
LULU, FRO and PMCB among pre market gainers